Roche’s Giredestrant NDA Accepted by FDA for Early Breast Cancer
BASEL, Switzerland, June 2, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the New...
AI drug discovery AI healthcare artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
BASEL, Switzerland, June 2, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has accepted the New...
SOUTH SAN FRANCISCO, Calif., June 1, 2026 Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted...
HONG KONG, SHANGHAI & FLORHAM PARK, N.J., April 29, 2026 HUTCHMED (China) Limited has announced that the New Drug...
Tokyo, Japan & Basking Ridge, New Jersey | April 13, 2026 Daiichi Sankyo, in collaboration with Merck & Co.,...
Hong Kong / Shanghai | December 30, 2025 — HUTCHMED announced that China’s drug regulator has accepted the New...
Stockholm, Sweden – October 31, 2025 — Immedica Pharma has announced that its New Drug Submission (NDS) for Loargys®...
San Rafael, California — October 30, 2025 — BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration...
ROSWELL, Ga., September 8, 2025 — Saol Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has...
